Hemolytic anemias due to erythrocyte enzyme deficiencies.
Red blood cells can only fulfil their functions over the normal period of approximately 120 days with 1.7 x 10(5) circulatory cycles efficiently if they withstand external and internal loads. This requires ATP and redox equivalents, which have to be permanently regenerated by the energy and redox metabolism. These pathways are necessary to maintain the biconcave shape of the cells, their specific intracellular cation concentrations, the reduced state of hemoglobin with a divalent iron and the sulfhydryl groups of enzymes, glutathione and membrane components. If an enzyme deficiency of one of these metabolic pathways limits the ATP and/or NADPH production, distinct membrane alterations result causing a removal of the damaged cells by the monocyte-macrophage system. Most metabolic needs of erythrocytes are covered by glycolysis, the oxidative pentose phosphate pathway (OPPP), the glutathione cycle, nucleotide metabolism and MetHb reductase. Hereditary enzyme deficiencies of all these pathways have been identified; those that cause non-spherocytic hemolytic anemia are listed in Table 4. Their frequencies differ markedly both with respect to the affected enzyme and geographic distribution. Glucose-6-phosphate dehydrogenase enzymopathies (G6PD) are with more than 400 million cases by far the most common deficiency. The highest gene frequency has been found with 0.7 among Kurdish Jews. G6PD deficiencies are furthermore prevalent with frequencies of about 0.1 among Africans, Black Americans, and populations of Mediterranean countries and South East Asia. In Middle and Northern Europe the frequency of G6PD is much lower, and with approximately 0.0005, comparable with the frequency of pyruvate kinase (PK) enzymopathies, the most frequent enzyme deficiency in glycolysis in this area (Luzzatto, 1987; Beutler and Kuhl, 1990). The relationship between the degree of enzyme deficiency and the extent of metabolic dysfunction in red blood cells and other tissues depend on several factors: on the importance of the affected enzyme; its expression rate; the stability of the mutant enzyme against proteolytic degradation and functional abnormalities; the possibility to compensate the deficiency by an overexpression of the corresponding isoenzyme or by the use of an alternative metabolic pathway. Difficulties in estimating the quantitative degree of disorder in severe cases are due to the fact that these populations contain many reticulocytes, which generally have higher enzyme activities and concentrations of intermediates than erythrocytes. An alternative approach to predict metabolic changes is the analysis by mathematical modeling. Mathematical modeling of the main metabolic pathways of human erythrocytes has reached an advanced level (Rapoport et al., 1976; Holzhütter et al., 1985; Schuster et al., 1988). Models have been successfully employed to describe stationary and time-dependent metabolic states of the cell under normal conditions as well as in the presence of enzyme deficiencies. Figure 5 shows computational results of erythrocyte enzyme deficiencies. This analysis is based on the comprehensive mathematical model of the energy and redox metabolism for human erythrocyte presented in Fig. 6. Stationary states of the cell metabolism have been calculated by varying the activity of each of the participating enzymes by several orders of magnitude. To predict consequences of enzyme deficiencies a performance function has been introduced (Schuster and Holzhütter, 1995). It takes into account the homeostasis of three essential metabolic variables: the energetic state (ATP), the reductive capacity (reduced glutathione) and the osmotic state. From the data given in Fig. 5 one can conclude that generally the metabolic impairment resulting in deficiencies occurs earlier for enzymes with high control coefficients than for those catalyzing equilibrium reactions. On the other hand the flux curves of latter enzymes decrease more steeply below a critica
Jacobasch
G
G
Institute of Biochemistry, Charité, Humboldt University, Berlin, Germany.
Rapoport
S M
SM
D000743:Anemia, Hemolytic / Q000503:physiopathology* / Q000628:therapy; D000746:Anemia, Hemolytic, Congenital Nonspherocytic; D001731:Bisphosphoglycerate Mutase / Q000172:deficiency / Q000235:genetics; D004734:Energy Metabolism; D004912:Erythrocytes / Q000201:enzymology* / Q000378:metabolism; D005828:Genetics, Population; D005956:Glucose-6-Phosphate Isomerase / Q000235:genetics; D005955:Glucosephosphate Dehydrogenase Deficiency / Q000235:genetics* / Q000378:metabolism*; D005978:Glutathione / Q000378:metabolism; D006593:Hexokinase / Q000172:deficiency / Q000235:genetics; D006801:Humans; D007700:Kinetics; D008288:Malaria; D009154:Mutation / Q000235:genetics; D010084:Oxidation-Reduction; D010427:Pentose Phosphate Pathway / Q000502:physiology; D010732:Phosphofructokinase-1 / Q000172:deficiency / Q000235:genetics; D011110:Polymorphism, Genetic / Q000235:genetics; D011770:Pyruvate Kinase / Q000172:deficiency / Q000235:genetics / Q000378:metabolism; D014305:Triose-Phosphate Isomerase / Q000172:deficiency / Q000235:genetics
D006593:Hexokinase; D010732:Phosphofructokinase-1; D011770:Pyruvate Kinase; D014305:Triose-Phosphate Isomerase; D005956:Glucose-6-Phosphate Isomerase; D001731:Bisphosphoglycerate Mutase; D005978:Glutathione